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Edited by Veli-Pekka LehtoAbstract The involvement of estrogen receptor beta (ER) in
prostate carcinogenesis has been hypothesized. Several reports
have shown that ER expression was decreased when prostate
cells undergo neoplastic transformation, suggesting that it could
play a tumor-suppressor role. By restoring ER expression in
prostatic carcinoma cells by adenoviral delivery, we aimed to test
this hypothesis. We observed that ER strongly inhibited the
invasiveness and the growth of these cells. In addition, ER cells
were undergoing apoptosis, as shown by quantiﬁcation of Bax,
Poly(ADP-ribose) polymerase and caspase-3 expression. Our
data suggest that ER acts as a tumor-suppressor by its anti-
proliferative, anti-invasive and pro-apoptotic properties.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Estrogen receptor; Apoptosis; Proliferation;
Invasion; Prostate cancer1. Introduction
Prostate cancer is one of the most common forms of cancer in
males in developed countries [1]. The role of sex steroids in the
biology of the prostate and prostate cancer remains unclear,
despite nearly four decades of research since Charles Huggins
dramatic demonstration of orchiectomy and endocrine therapy
on prostate cancer [2]. Until 1996, it was thought that estrogen
receptors (ER) are present only in a limited number of cells in
the prostate, mainly in the stromal cells of the prostatic lobes
and the posterior periurethral region, while the epithelial cells
were reported to contain very low amounts of the receptors [3].
However, the recent discovery of a novel ERb, cloned from rat
prostate cDNA library, and abundantly expressed in rat and
human prostate epithelium [4], suggests that prostate epithe-
lium is also a direct target for estrogen action. Moreover, a
recent study has shown that ERb is the only ER detected at the
protein level in the morphologically normal developing human
fetal prostate [5]. Since the identiﬁcation of ERb, many reports
have shown that a loss of ERb expression is associated with* Corresponding author. Fax: +33-4-67-54-30-84.
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[6–9]. A similar down-regulation in ERb expression is also
noted in ovarian, breast or colon tumors [10–12]. These data
and the observation that older ERb-null mice develop prostatic
hyperplasia [13] have led to the hypothesis that the loss of ERb
may be a mechanism by which prostate epithelial cells escape
normal control of proliferation [14]. The goal of this study was
to determine whether restoration of ERb expression in prostate
cancer cells had major eﬀect on proliferation, invasiveness and
apoptosis of prostate cancer cells.2. Materials and methods
2.1. Recombinant adenovirus construction and propagation
The complete coding sequences of wild-type hERa and hERb
cDNAs were subcloned in BamHI site of the pACsk12CMV5 shuttle
vector. To obtain recombinant viruses, permissive HEK-293 cells
(human embryonic kidney cells) were cotransfected with the backbone
or recombinant pACsk12CMV5-hER plasmid and with pJM17, which
contains the remainder of the adenoviral genome as previously de-
scribed [15,16]. In vivo recombination of the plasmids generates in-
fectious viral particles Ad5 (backbone virus), Ad-hERa and Ad-hERb.
Titered virus stocks were used to infect DU-145 prostate cancer cells.
2.2. Cell culture and infection
DU-145 cells (ER-negative) were obtained from the American Type
Culture Collection (ATCC Rockville, MD). Cells were maintained in
MEM with 5% FCS and penicillin/streptomycin (Invitrogen). DU-145
cells were weaned oﬀ steroids in phenol red-free MEM supplemented
with 10% CDFCS (charcoal dextran-treated FCS) 3 days before ex-
periments. Cells were infected overnight at a multiplicity of infection
(MOI) of 50. The next day, the medium was removed and replaced
with fresh one.
2.3. Transfections
3 105 cells were plated in 6-well plates in phenol red-free MEM
10% CDFCS 24 h before infection. Cells were then infected overnight
as speciﬁed in Section 2.2. The next day, transfections were performed
with lipofectamine according to the manufacturer’s recommendations
using 4 lg of ERE2-TK-LUC luciferase reporter along with 0.8 lg of
the internal reference reporter plasmid (CMV-Gal) per well. After
overnight lipofection, the medium was removed and the cells were
placed into fresh medium supplemented with control vehicle ethanol or
E2 (108 M). 24 h later, cells were harvested and assayed for luciferase
activity on Centro LB960 Berthold luminometer. b-Galactosidase was
determined as previously described [15].
2.4. Whole cell extract preparation and Western blot
Cells were lyzed by sonication in 10 mM Tris–HCl, pH 7.4, 1.5 mM
EDTA, and 10% glycerol containing protease inhibitors. The resulting






170 J. Cheng et al. / FEBS Letters 566 (2004) 169–172electrotransfer onto a nitrocellulose membrane. The following anti-
bodies were used: Bax monoclonal antibody, B/9 (Santa Cruz Bio-
technologies; 1:500 dilution); and Poly(ADP-ribose) polymerase
(PARP) monoclonal antibody, 4C10-5 (BD Pharmingen; 1 lg/ml).
2.5. Immunoﬂuorescence
106 cells were plated in a 6-well plate and infected with adenovirus at
a MOI of 50. Paraformaldehyde ﬁxed cells were incubated with pri-
mary antibody against cleaved caspase 3 (Cell Signaling Technologies)
for 1 h at room temperature in a humidiﬁed chamber. After washing
with Tris-buﬀered saline + 0.025% Tween, staining was performed
using biotinylated secondary antibodies (ABC kit, Vector Laborato-
ries), and streptavidin–FITC (1:100, Vector Laboratories). Cell images
were analyzed using a Zeiss microscope (Axioskop, Carl Zeiss Inc.,
Oberkochen, Germany).
2.6. Transwell matrigel invasion assays
Invasion was performed as previously described [15]. Brieﬂy, DU-
145 cells were plated 24 h after infection (MOI 50) in the upper
compartment ﬁlled with MEM 10% CDFCS with 30 lg/ml ﬁbronectin
of a 24-well Transwell (Corning-Costar) on a polycarbonate ﬁlter (8
lm pore size), which was pre-coated with 30 lg of matrigel (Becton–
Dickinson). Cells migrating to the lower side of the ﬁlter and control
cells in the 24-well plate were quantiﬁed using MTT uptake (Sigma
Chemical Co., St. Louis, MO).
2.7. Cell proliferation assays
Cells were estrogen depleted for 3 days and then plated in 96-well
plates at a density of 5000 cells/well and infected with adenovirus
overnight (MOI 50). MEM 10% CDFCS containing either ethanol or















3.1. ERb introduction in prostate cancer cells
To test this hypothesis of the involvement of ERb in prostate
cell growth, we decided to restore ERa and ERb expression in
the ER-negative prostate carcinoma cell line DU-145, by using
ERa or ERb encoding adenoviruses. Cells were mock infected
(non-infected) or infected with backbone (Ad5), ERa (Ad-
ERa), or ERb (Ad-ERb) adenoviruses. No detectable levels of
ERa or ERb proteins were seen by immunoblotting or im-
munoﬂuorescence in uninfected or Ad5 infected cells, whereas













Fig. 1. Adenovirus mediated expression of ERa and ERb in DU-145
cells. DU-145 cells were either infected with Ad5, Ad-ERa, Ad-ERb
viruses and transfected with ERE2-TK-LUC and CMV-GAL reporter
constructs. Cells were grown for 48 h in the presence of control vehicle
ethanol (C) or 108 M E2. Results represent meansSEM of three
independent experiments.proteins (data not shown). To further assess the functionality
of the receptors, virally expressed ERa and ERb were able to
transactivate an estrogen-responsive reporter construct when
transfecting DU-145 cells (Fig. 1). Both receptors were active,
even though ERb was a weaker activator than ERa, as pre-
viously shown in breast cancer cells [15,17].
3.2. ERb inhibits prostate cancer cell invasiveness and growth
We next examined the consequences of ERa or ERb ex-
pression on the invasion potential of DU-145 cells by using
matrigel-coated Transwell (Fig. 2A). Ad-ERa infected cells
had the same invasion potential as Ad5 infected cells (Fig. 2A).
With the addition of estradiol, a 30–40% decrease in invasion
was observed. Interestingly, in ERb infected cells, in the ab-
sence of estrogens, a 50% decrease in invasion was observed.
With the addition of E2, an even greater inhibition of invasion
was observed, up to 70% of baseline (Fig. 2A).
In addition to invasion, another major goal of these experi-
ments was to determine the eﬀect of ERa and ERb on prolifer-
ation in DU-145 cells. Ad-ERa infected cells in control medium









Fig. 2. Ad-ERa and Ad-ERb inhibit cellular invasion and growth (A)
DU-145 cells were infected with Ad5, Ad-ERa, and Ad-ERb adeno-
viruses at MOI 50 and were plated on a transwell chamber coated with
matrigel. Cells were treated with either ethanol (C) or 10 nM E2 and
allowed to invade the matrigel for 24 h. Results represent means
SEM of three independent experiments. (B) DU-145 cells were plated
in a 96-well plate and infected with Ad5, Ad-ERa, or Ad-ERb ade-
noviruses overnight at MOI 50. Fresh media containing either ethanol
or 10 nM E2 were added to the cells and proliferation was deter-
mined 6 days post infection. Results are expressed as % of control
non-infected cells and represent mean SEM of three independent
experiments.
Fig. 3. ERb induces apoptosis in DU-145 cells. Estrogen depleted cells
were infected with Ad5 or Ad-ERb adenoviruses overnight at MOI 50.
Cells were then grown for 24 or 48 h and whole cell lysates were col-
lected. (A) Immunoblotting using anti-Bax monoclonal antibody was
performed. (B) Immunoblotting using anti-PARP monoclonal anti-
body. This antibody recognizes both intact and the 85 kDa cleaved
fragment of PARP. (C) Paraformaldehyde ﬁxed cells were incubated
with primary antibodies against cleaved caspase 3 and examined by
immunoﬂuorescence. Nuclei were stained using DAPI containing
mounting medium.
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ERa cells treated with estradiol. On the contrary, Ad-ERb cells
displayed a 60% decreased proliferation in both control and
estradiol treated conditions. These data suggest that although
both ERa and ERb inhibit proliferation, ERb is a stronger
regulator of cell growth than ERa in prostate cancer cells.
3.3. ERb is triggering apoptosis of prostate cancer cells
We next hypothesized the potential involvement of apop-
tosis behind the decrease in proliferation seen in Ad-ERb
cells. To answer to this question, we analyzed the expression
of several markers of apoptosis. Introduction of ERb in DU-
145 cells led to a strong increase in pro-apoptotic Bax levels
(Fig. 3A). PARP, a caspase target, was also analyzed. Levels
of cleaved PARP (85 kDa) were increased in Ad-ERb in-
fected cells compared to Ad5 infected cells. To further
characterize the apoptosis seen in Ad-ERb cells, immuno-
ﬂuorescence with anti-cleaved caspase 3 antibodies was per-
formed (Fig. 3C). Introduction of ERb in DU-145 cells led to
peri-nuclear expression of cleaved caspase 3 (Fig. 3C). All
these data suggest that cells expressing ERb undergo apop-
tosis, which could contribute to the reduced proliferation
observed.4. Discussion
Prostate is considered together with ovary as one of the main
tissue in terms of ERb expression [4]. Moreover, several studies
have shown a decreased expression of ERb in prostate carci-
noma compared to non-pathological tissues [6–9]. The poten-
tial beneﬁcial anti-neoplastic role of ERb in prostate is thus
crucial but remains to be demonstrated. To investigate theroles of ERa and ERb in prostate, we used a prostate cancer
cell line devoid of both endogenous receptors in which ERa
and ERb expression was restored using adenovirus delivery.
Interestingly, a potent decrease in invasion (60%) was observed
with the introduction of ERb, which is in agreement with the
situation found in breast cancer cells [15]. The results from the
invasion assay also correlate with the emerging clinical data.
At least three diﬀerent reports show that the loss or decrease in
ERb expression is associated with higher Gleason grade
tumors and prostate cancer with higher metastatic potential
[6–8].
Concerning cell growth, the introduction of ERb in DU-145
cells caused a strong inhibition of proliferation, in agreement
with our previous data in breast cell carcinoma [15], and with
the more recent studies showing that ERb can also inhibit the
proliferation of ERa-positive breast cancer cells [18,19]. These
data correlate well with the phenotype of ERb knock-out an-
imals (bERKO) studies in which, most breast and prostate
epithelial cells express the proliferation antigen Ki-67 [14].
Moreover, 80% of 1-year-old bERKO animals show hyper-
plastic lesions in prostate, suggesting that the loss of ERb leads
to an uncontrolled cellular proliferation. The mechanisms re-
sponsible for the reduced growth of cells exogenously ex-
pressing ERb are beginning to be investigated. We and others
have shown that ERb was able to induce p21Cip-1 and p27Kip-1
expression, while decreasing c-myc, cyclin A, cyclin D1, cyclin
E, Cdc25A, and p45 (Skp2) levels [15,18,19]. Moreover, at
least in ERa-positive breast cancer cells, growth inhibition
would result from an arrest in G2 phase of the cell cycle [18].
Concerning the fact that ERa decreases both the invasion
and the proliferation in a ligand-dependent manner, several
hypotheses can be raised. We have previously shown by a
cDNA array screen and western blot analysis that introduction
of ERa in ER-negative breast cancer cells leads to striking
changes in gene expression. In particular, levels of p21CIP-1,
p27Kip-1, macmarcks and TOB are increased, whereas pRb
protein is hypo-phosphorylated, suggesting that these events
could account for the estrogen-dependent observed growth
inhibition [20]. In the same line, changes in integrin and
BMP-4 [20] could also account for the observed inhibition of
invasion observed after reintroduction of ERa. For ERb, the
situation is indeed diﬀerent as this receptor inhibits both the
invasion and the proliferation, mainly in a ligand-independent
manner. We have previously shown that ERb could inhibit
Interleukin-8 (IL-8) expression in a ligand independent manner
[21]. Moreover, IL-8 is able to increase invasion, which sug-
gests that at least part of the eﬀects of ERb on invasion could
involve a decreased expression of IL-8. The mechanisms ac-
counting for the ligand-independent inhibition of growth re-
main elusive. We cannot entirely rule out the possibility of an
endogenous cryptic ERb ligand. Indeed, Weihua et al. [22]
have proposed that the testosterone metabolite 5a-androstane-
3b-diol (3bAdiol) could be a potential ligand of ERb. There-
fore, it is possible that prostate cancer cells auto-synthesize
sex-steroids, which could function as natural activators of
ERb. In addition, it has also been shown that unliganded ER
can transduce growth factor signals [23]. ERb is able to recruit
the coactivator, SRC-1 through phosphorylation of Ser-106
and Ser-124 by MAPK in a ligand independent manner [24].
Perhaps the ligand independent ERb action in apoptosis in-
volves SRC-1 interaction, or some yet unidentiﬁed pathway
that is unique to ERb AF-1 activity.
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growth inhibition triggered by ERb is due to apoptosis,
demonstrating the involvement of ERb in such events.
Apoptosis of the ERb expressing cells was shown by the in-
creased peri-nuclear expression of cleaved caspase 3. The
apoptosis induced by ERb appears to involve the mito-
chondrial pathways, as demonstrated by the increase in Bax
protein expression and the cleavage of PARP. To our
knowledge, this is one of the ﬁrst demonstration that ERb is
able to trigger apoptosis. Indeed, a recent study has shown
that ERb could increase apoptosis in colon cancer cells [25].
A detailed analysis of this phenomenon will need to be un-
dertaken in the future.
The fact that exogenous expression of ERb in prostate
cancer cells leads to an inhibition of proliferation and invasion
and to an increase of apoptosis is in good agreement with
clinical studies showing that ERb expression is lost in prostate,
breast, ovary, and colon tissues when they undergo dysplastic
transformation [7,10,12]. The reasons underlying ERb loss
remain poorly understood. Human ERb promoter has been
cloned recently [26] and could help to study this phenomenon.
The promoter is active only in ERb expressing cells and dis-
plays a high GC-content. Interestingly, another study has
shown that ERb promoter was methylated in about 80% of
cancers but not in normal tissues [27], which could explain the
down regulation of ERb observed in cancer cells. The under-
standing of ERb expression regulation will deﬁnitely constitute
a challenging issue in the future, as it could lead to the de-
velopment of new therapies.
In conclusion, our data strongly support the hypothesis that
the loss of ERb could be one of the key elements leading to an
uncontrolled growth of prostate epithelial cells. In this model,
ERb would play a ‘‘gatekeeper’’ role by inhibiting invasion,
proliferation and stimulating apoptosis, preventing the rapidly
diﬀerentiating prostatic epithelial cells from undergoing on-
cogenic transformation.
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